{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T09:57:36Z","timestamp":1675850256143},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T00:00:00Z","timestamp":1307491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s11914-011-0061-4","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T10:57:25Z","timestamp":1307444245000},"page":"156-159","source":"Crossref","is-referenced-by-count":1,"title":["Choosing a Treatment for Patients at the Time a Fracture is Presented"],"prefix":"10.1007","volume":"9","author":[{"given":"S. Bobo","family":"Tanner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,8]]},"reference":[{"key":"61_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2000;15:721\u201339.","journal-title":"J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"61_CR2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ageing\/afp221","volume":"39","author":"PN Kannegaard","year":"2010","unstructured":"Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39:203\u20139.","journal-title":"Age Ageing"},{"key":"61_CR3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00198-005-1950-0","volume":"16","author":"AC Feldstein","year":"2005","unstructured":"Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16:953\u201362.","journal-title":"Osteoporos Int"},{"key":"61_CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jocd.2008.04.003","volume":"11","author":"NB Watts","year":"2008","unstructured":"Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11:473\u20137.","journal-title":"J Clin Densitom"},{"key":"61_CR5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-149-6-200809160-00007","volume":"149","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404\u201315.","journal-title":"Ann Intern Med"},{"issue":"supplement 3","key":"61_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","volume":"16","author":"BJ Watts NB","year":"2010","unstructured":"\u2022 Watts NB BJ, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of post menopausal osteoporosis. Endocr Pract. 2010;16 supplement 3:1\u201337. This is a comprehensive and useful set of guidleines for the management of osteoporosis.","journal-title":"Endocr Pract"},{"key":"61_CR7","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","volume":"87","author":"C Tannenbaum","year":"2002","unstructured":"Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"61_CR8","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S1297-319X(10)70009-9","volume":"77","author":"N Mehsen","year":"2010","unstructured":"\u2022\u2022 Mehsen N, Paccou J, Confavreux CB, et al. Management of patients with incident fractures during osteoporosis treatment. Joint Bone Spine 2010;77 Suppl 2:S133\u20138. This article has a thoughtful series of six questions to use when evaluating the fracture patient already on osteoporosis treatment to help calrify if the patient is a \u201ctreatment failure\u201d and how to procede.","journal-title":"Joint Bone Spine"},{"key":"61_CR9","doi-asserted-by":"crossref","unstructured":"Nurmi-L\u00fcthje I, Sund R, Juntunen M, L\u00fcthje P. Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and anti-osteoporotic drugs are associated with lower mortality. A nationwide study in Finland. J Bone Miner Res. 2011;n\/a\u2013n\/a.","DOI":"10.1002\/jbmr.375"},{"key":"61_CR10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/SMJ.0b013e3181ebe96c","volume":"103","author":"PC Gregory","year":"2010","unstructured":"Gregory PC, Lam D, Howell P. Osteoporosis treatment following hip fracture: how rates vary by service. South Med J. 2010;103:977\u201381.","journal-title":"South Med J"},{"key":"61_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.18553\/jmcp.2008.14.S3-A.2","volume":"14","author":"GM Owens","year":"2008","unstructured":"Owens GM. Gender differences in health care expenditures, resource utilization, and quality of care. J Manag Care Pharm. 2008;14:2\u20136.","journal-title":"J Manag Care Pharm"},{"key":"61_CR12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/art.23093","volume":"57","author":"JT Harrington","year":"2007","unstructured":"Harrington JT, Lease J. Osteoporosis disease management for fragility fracture patients: New understandings based on three years\u2019 experience with an osteoporosis care service. Arthritis Care Res. 2007;57:1502\u20136.","journal-title":"Arthritis Care Res"},{"key":"61_CR13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00198-003-1430-3","volume":"14","author":"MW Cree","year":"2003","unstructured":"Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003;14:722\u20137.","journal-title":"Osteoporos Int"},{"key":"61_CR14","first-page":"89","volume":"29","author":"L Semerano","year":"2011","unstructured":"\u2022 Semerano L, Guillot X, Rossini M, et al. What predicts initiation of osteoporosis treatment after fractures: education organisation or patients\u2019 characteristics? Clin Exp Rheumatol 2011;29:89\u201392. This recent work speaks to the need for predischarge treatment initiation of osteoporosis treatment when a patient has been hospitalized with a fragility fracture.","journal-title":"Clin Exp Rheumatol"},{"key":"61_CR15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PHM.0b013e31805b7e20","volume":"86","author":"GM Kiebzak","year":"2007","unstructured":"Kiebzak GM, Moore NL, Margolis S, et al. Vitamin D status of patients admitted to a hospital rehabilitation unit: relationship to function and progress. Am J Phys Med Rehabil. 2007;86:435\u201345.","journal-title":"Am J Phys Med Rehabil"},{"key":"61_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-010-9360-5","volume":"87","author":"M Ellegaard","year":"2010","unstructured":"Ellegaard M, J\u00f8rgensen N, Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int. 2010;87:1\u201313.","journal-title":"Calcif Tissue Int"},{"key":"61_CR17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11914-010-0006-3","volume":"8","author":"S Bukata","year":"2010","unstructured":"\u2022 Bukata S, Puzas J. Orthopedic Uses of Teriparatide. Curr Osteoporos Rep. 2010;8:28\u201333. This is an excellent review of the details of teriparitide and its effects on fracture and bone healing.","journal-title":"Curr Osteoporos Rep"},{"key":"61_CR18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1359\/jbmr.070724","volume":"22","author":"S Kakar","year":"2007","unstructured":"Kakar S, Einhorn TA, Vora S, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res. 2007;22:1903\u201312.","journal-title":"J Bone Miner Res"},{"key":"61_CR19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","volume":"25","author":"P Aspenberg","year":"2010","unstructured":"Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2010;25:404\u201314.","journal-title":"J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"61_CR20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00198-009-1061-4","volume":"21","author":"S Chintamaneni","year":"2010","unstructured":"Chintamaneni S, Finzel K, Gruber B. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos Int. 2010;21:1059\u201363.","journal-title":"Osteoporos Int"},{"key":"61_CR21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2106\/JBJS.G.01443","volume":"90","author":"GL Barnes","year":"2008","unstructured":"Barnes GL, Kakar S, Vora S, et al. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am. 2008;90:120\u20137.","journal-title":"J Bone Joint Surg Am"},{"key":"61_CR22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1210\/jc.2010-2520","volume":"96","author":"SJ Gomberg","year":"2011","unstructured":"Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, Vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96:1627\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"61_CR23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10067-010-1486-3","volume":"29","author":"M Maricic","year":"2010","unstructured":"Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol. 2010;29:1079\u201384.","journal-title":"Clin Rheumatol"},{"key":"61_CR24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/jbmr.5650111016","volume":"11","author":"E Beek Van","year":"1996","unstructured":"Van Beek E, Lowik C, Que I, Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 1996;11:1492\u20137.","journal-title":"J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"61_CR25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677\u201392.","journal-title":"Bone"},{"key":"61_CR26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ijc.21977","volume":"119","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Hulley PA, Meijer A, et al. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer. 2006;119:1254\u201361.","journal-title":"Int J Cancer"},{"key":"61_CR27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/000164700317413193","volume":"71","author":"P Adolphson","year":"2000","unstructured":"Adolphson P, Abbaszadegan H, Boden H, et al. Clodronate increases mineralization of callus after Colles\u2019 fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand. 2000;71:195\u2013200.","journal-title":"Acta Orthop Scand"},{"key":"61_CR28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1359\/jbmr.2000.15.3.586","volume":"15","author":"E Poest Clement Van Der","year":"2000","unstructured":"Van Der Poest Clement E, Patka P, Vandormael K, et al. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res. 2000;15:586\u201393.","journal-title":"J Bone Miner Res"},{"key":"61_CR29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799\u2013809.","journal-title":"N Engl J Med"},{"key":"61_CR30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77\u201385.","journal-title":"Clin Breast Cancer"},{"key":"61_CR31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14:801\u20137.","journal-title":"Osteoporos Int"},{"key":"61_CR32","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Bukata SV. Systemic administration of pharmacological agents and bone repair: What can we expect. Injury 2011;In Press. This is the best summary of the current and future pharmacologic agents used with osteoporosis treatment and bone healing.","DOI":"10.1016\/j.injury.2011.03.061"},{"key":"61_CR33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bone.2008.05.019","volume":"43","author":"MM McDonald","year":"2008","unstructured":"McDonald MM, Dulai S, Godfrey C, et al. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008;43:653\u201362.","journal-title":"Bone"},{"key":"61_CR34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1359\/jbmr.070318","volume":"22","author":"N Amanat","year":"2007","unstructured":"Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22:867\u201376.","journal-title":"J Bone Miner Res"},{"key":"61_CR35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhsa.2008.12.011","volume":"34","author":"TD Rozental","year":"2009","unstructured":"Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg. 2009;34:595\u2013602.","journal-title":"J Hand Surg"},{"key":"61_CR36","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1359\/jbmr.090209","volume":"24","author":"EF Eriksen","year":"2009","unstructured":"Eriksen EF, Lyles KW, Col\u00f3n-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24:1308\u201313.","journal-title":"J Bone Miner Res"},{"key":"61_CR37","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bone.2010.01.377","volume":"46","author":"TM Thillemann","year":"2010","unstructured":"Thillemann TM, Pedersen AB, Mehnert F, et al. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010;46:946\u201351.","journal-title":"Bone"},{"key":"61_CR38","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2004;19:1779\u201386.","journal-title":"J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"61_CR39","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. N Engl J Med. 2010;362:1761\u201371.","journal-title":"N Engl J Med"},{"key":"61_CR40","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher J, Micha\u00eblsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728\u201337.","journal-title":"N Engl J Med"},{"key":"61_CR41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bone.2004.04.016","volume":"35","author":"C Milgrom","year":"2004","unstructured":"Milgrom C, Finestone A, Novack V, et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone. 2004;35:418\u201324.","journal-title":"Bone"},{"key":"61_CR42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"key":"61_CR43","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2010;25:2256\u201365.","journal-title":"J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"61_CR44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","volume":"11","author":"PD Delmas","year":"2008","unstructured":"Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008;11:325\u201338.","journal-title":"J Clin Densitom"},{"key":"61_CR45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1359\/jbmr.081113","volume":"24","author":"LC Gerstenfeld","year":"2009","unstructured":"Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009;24:196\u2013208.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"61_CR46","first-page":"S243","volume":"22","author":"S Adami","year":"2011","unstructured":"Adami S, Palacios S, Pavalka K, et al. FREEDOM TRIAL: densoumab is not associated with fracture healing complications in postmenopausal women with osteoporosis. Osteoporos Int. 2011;22 Suppl 1:S243\u20134.","journal-title":"Osteoporos Int"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-011-0061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-011-0061-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-011-0061-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T18:37:06Z","timestamp":1637779026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-011-0061-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s11914-011-0061-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,8]]}}}